. 2018 Jan;118(2):266-276.

doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Christos Mikropoulos¹, Christina G Hutten Selkirk^{2

3}, Sibel Saya¹, Elizabeth Bancroft^{1

4}, Emily Vertosick⁵, Tokhir Dadaev¹, Charles Brendler², Elizabeth Page¹, Alexander Dias^{1

4}, D Gareth Evans⁶, Jeanette Rothwell⁶, Lovise Maehle⁷, Karol Axcrona⁸, Kate Richardson^{9

10}, Diana Eccles^{11

12}, Thomas Jensen¹³, Palle J Osther¹³, Christi J van Asperen¹⁴, Hans Vasen¹⁵, Lambertus A Kiemeney¹⁶, Janneke Ringelberg¹⁵, Cezary Cybulski¹⁷, Dominika Wokolorczyk¹⁷, Rachel Hart¹⁸, Wayne Glover¹⁸, Jimmy Lam¹⁹, Louise Taylor¹⁹, Monica Salinas²⁰, Lidia Feliubadaló²⁰, Rogier Oldenburg²¹, Ruben Cremers¹⁶, Gerald Verhaegh¹⁶, Wendy A van Zelst-Stams¹⁵, Jan C Oosterwijk²², Jackie Cook²³, Derek J Rosario²⁴, Saundra S Buys²⁵, Tom Conner²⁵, Susan Domchek²⁶, Jacquelyn Powers²⁶, Margreet Gem Ausems²⁷, Manuel R Teixeira^{28

29}, Sofia Maia²⁸, Louise Izatt³⁰, Rita Schmutzler³¹, Kerstin Rhiem³¹, William D Foulkes³², Talia Boshari³², Rosemarie Davidson³³, Marielle Ruijs³⁴, Apollonia Tjm Helderman-van den Enden³⁵, Lesley Andrews³⁶, Lisa Walker³⁷, Katie Snape³⁸, Alex Henderson³⁹, Irene Jobson³⁹, Geoffrey J Lindeman^{40

41

42}, Annelie Liljegren⁴³, Marion Harris⁴⁴, Muriel A Adank⁴⁵, Judy Kirk^{46

47}, Amy Taylor⁴⁸, Rachel Susman⁴⁹, Rakefet Chen-Shtoyerman⁵⁰, Nicholas Pachter^{51

52}, Allan Spigelman^{53

54

55}, Lucy Side⁵⁶, Janez Zgajnar⁵⁷, Josefina Mora⁵⁸, Carole Brewer^{59

60}, Neus Gadea⁶¹, Angela F Brady⁶², David Gallagher⁶³, Theo van Os⁶⁴, Alan Donaldson⁶⁵, Vigdis Stefansdottir⁶⁶, Julian Barwell^{67

68}, Paul A James^{9

10

69}, Declan Murphy¹⁰, Eitan Friedman^{70

71}, Nicola Nicolai⁷², Lynn Greenhalgh⁷³, Elias Obeid⁷⁴, Vedang Murthy⁷⁵, Lucia Copakova⁷⁶, John McGrath⁶⁰, Soo-Hwang Teo⁷⁷, Sara Strom⁷⁸, Karin Kast^{79

80

81}, Daniel A Leongamornlert¹, Anthony Chamberlain¹, Jenny Pope¹, Anna C Newlin³, Neil Aaronson³⁴, Audrey Ardern-Jones⁴, Chris Bangma²¹, Elena Castro⁸², David Dearnaley^{1

4}, Jorunn Eyfjord⁸³, Alison Falconer⁸⁴, Christopher S Foster⁸⁵, Henrik Gronberg⁸⁶, Freddie C Hamdy^{37

87}, Oskar Johannsson⁶⁶, Vincent Khoo⁴, Jan Lubinski¹⁷, Eli Marie Grindedal⁷, Joanne McKinley⁹, Kylie Shackleton⁴⁰, Anita V Mitra⁸⁸, Clare Moynihan¹, Gad Rennert⁸⁹, Mohnish Suri⁹⁰, Karen Tricker⁶; IMPACT study collaborators; Sue Moss⁹¹, Zsofia Kote-Jarai¹, Andrew Vickers⁵, Hans Lilja^{87

92}, Brian T Helfand², Rosalind A Eeles^{1

4}

Affiliations

¹ The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
² The John and Carol Walter Center for Urological Health, Department of Surgery, North Shore University Health System, Evanston, IL 60201, USA.
³ Center for Medical Genetics, Department of Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.
⁴ Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK.
⁵ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
⁶ Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK.
⁷ Department of Medical Genetics, Oslo University Hospital, Oslo 0372, Norway.
⁸ Akershus University Hospital, Lørenskog 1478, Norway.
⁹ Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, VIC 3000, Australia.
¹⁰ The Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3010, Australia.
¹¹ Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton SO16 5YA, UK.
¹² Cancer Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK.
¹³ Department of Clinical Genetics, Vejle Hospital, Vejle 7100, Denmark.
¹⁴ Leiden University Medical Center, Department of Clinical Genetics, Leiden, ZA 2333, The Netherlands.
¹⁵ Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, ZA 2333, The Netherlands.
¹⁶ Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.
¹⁷ International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-204, Poland.
¹⁸ Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham B15 2TG, UK.
¹⁹ Department of Urology, Repatriation General Hospital, Daw Park, SA 5041, Australia.
²⁰ Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L'Hospitalet de Llobregat, Barcelona 08908, Spain.
²¹ Department of Clinical Genetics, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.
²² Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen 9713 GZ, The Netherlands.
²³ Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield S10 2TH, UK.
²⁴ Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
²⁵ Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT 84103, USA.
²⁶ Basser Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
²⁷ Department of Genetics, University Medical Centre Utrecht, Utrecht, CX, The Netherlands.
²⁸ Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal.
²⁹ Biomedical Sciences Institute (ICBAS), Porto University, Porto 4200-072, Portugal.
³⁰ South East Thames Genetics Service, Guy's Hospital, London SE1 9RT, UK.
³¹ Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne 50937, Germany.
³² McGill Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada.
³³ Duncan Guthrie Institute of Medical Genetics, Yorkhill NHS Trust, Glasgow G38SJ, UK.
³⁴ The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
³⁵ Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, HX 6229, The Netherlands.
³⁶ Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
³⁷ Churchill Hospital, Headington, Oxford OX3 7LE, UK.
³⁸ St George's Hospital, Tooting, London SW17 0QT, UK.
³⁹ Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle NE1 3BZ, UK.
⁴⁰ Parkville Familial Cancer Centre, The Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia.
⁴¹ Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3050, Australia.
⁴² Department of Medicine, The University of Melbourne, Parkville, VIC 3050, Australia.
⁴³ Karolinska University Hospital and Karolinska Institutet, Solna 171 77, Sweden.
⁴⁴ Familial Cancer Centre, Monash Health, Clayton, VIC 3168, Australia.
⁴⁵ VU University Medical Center, Amsterdam 1081 HV, The Netherlands.
⁴⁶ Familial Cancer Service, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
⁴⁷ Centre for Cancer Research, The Westmead Institute for Medical Research, Westmead, Sydney, NSW 2155, Australia.
⁴⁸ Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
⁴⁹ Genetic Health Queensland, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia.
⁵⁰ The Genetic Institute, Kaplan Medical Center, Rehovot 76100, Israel.
⁵¹ Genetic Services of WA, King Edward Memorial Hospital, Subiaco, WA 6008, Australia.
⁵² School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia.
⁵³ Hunter Family Cancer Service, Waratah, NSW 2298, Australia.
⁵⁴ University of New South Wales, St Vincent's Clinical School, NSW 2052, Australia.
⁵⁵ The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW 2010, Australia.
⁵⁶ NE Thames Regional Genetics Service, Great Ormond St Hospital & UCL Institute of Women's Health, London WC1N 3JH, UK.
⁵⁷ Institute of Oncology, Ljubljana 1000, Slovenia.
⁵⁸ Hospital de Sant Pau, Barcelona 08041, Spain.
⁵⁹ Peninsular Genetics, Derriford Hospital, Plymouth PL6 8DH, UK.
⁶⁰ Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK.
⁶¹ High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona 08035, Spain.
⁶² North West Thames Regional Genetics Service, London North West Healthcare NHS Trust, London HA1 3UJ, UK.
⁶³ St James' Hospital, Dublin 8, Ireland.
⁶⁴ Academic Medical Center, Amsterdam 1105 AZ, The Netherlands.
⁶⁵ St Michael's Hospital, Bristol BS2 8EG, UK.
⁶⁶ Landspitali-the National University Hospital of Iceland, Reykjavik 101, Iceland.
⁶⁷ University of Leicester, Leicester LE1 7RH, UK.
⁶⁸ University Hospitals Leicester, Leicester LE1 5WW, UK.
⁶⁹ Genetic Medicine, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.
⁷⁰ Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.
⁷¹ Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
⁷² Istituto Nazionale dei Tumori, Milano 20133, Italy.
⁷³ Cheshire and Mersey Clinical Genetics Service, Liverpool Women's Hospital, Liverpool L8 7SS, UK.
⁷⁴ Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
⁷⁵ Tata Memorial Centre, Mumbai, Maharashtra 400012, India.
⁷⁶ National Cancer Institute, Bratislava 83310, Slovak Republic.
⁷⁷ Cancer Research Initiatives Foundation, Subang Jaya Medical Centre, Subang Jaya, Selangor 47500, Darul Ehsan, Malaysia.
⁷⁸ The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
⁷⁹ Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01069, Germany.
⁸⁰ National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden 01307, Germany.
⁸¹ German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
⁸² Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid 28029, Spain.
⁸³ Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik 101, Iceland.
⁸⁴ Imperial College Healthcare NHS Trust, London, London W2 1NY, UK.
⁸⁵ HCA Healthcare Laboratories, London WC1E 6JA, UK.
⁸⁶ University Hospital, Umea 907 37, Sweden.
⁸⁷ Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 2JD, UK.
⁸⁸ University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK.
⁸⁹ CHS National Cancer Control Center, Carmel Medical Center, Haifa 3436212, Israel.
⁹⁰ Nottingham City Hospital, Nottingham NG5 1PB, UK.
⁹¹ Centre for Cancer Prevention, Queen Mary University of London, London EC1M 6BQ.
⁹² Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

PMID: 29301143
PMCID: PMC5785754
DOI: 10.1038/bjc.2017.429

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Christos Mikropoulos et al. Br J Cancer. 2018 Jan.

. 2018 Jan;118(2):266-276.

doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4.

Authors

Affiliations

¹ The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
² The John and Carol Walter Center for Urological Health, Department of Surgery, North Shore University Health System, Evanston, IL 60201, USA.
³ Center for Medical Genetics, Department of Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.
⁴ Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK.
⁵ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
⁶ Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK.
⁷ Department of Medical Genetics, Oslo University Hospital, Oslo 0372, Norway.
⁸ Akershus University Hospital, Lørenskog 1478, Norway.
⁹ Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, VIC 3000, Australia.
¹⁰ The Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3010, Australia.
¹¹ Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton SO16 5YA, UK.
¹² Cancer Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK.
¹³ Department of Clinical Genetics, Vejle Hospital, Vejle 7100, Denmark.
¹⁴ Leiden University Medical Center, Department of Clinical Genetics, Leiden, ZA 2333, The Netherlands.
¹⁵ Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, ZA 2333, The Netherlands.
¹⁶ Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.
¹⁷ International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-204, Poland.
¹⁸ Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham B15 2TG, UK.
¹⁹ Department of Urology, Repatriation General Hospital, Daw Park, SA 5041, Australia.
²⁰ Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L'Hospitalet de Llobregat, Barcelona 08908, Spain.
²¹ Department of Clinical Genetics, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.
²² Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen 9713 GZ, The Netherlands.
²³ Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield S10 2TH, UK.
²⁴ Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
²⁵ Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT 84103, USA.
²⁶ Basser Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
²⁷ Department of Genetics, University Medical Centre Utrecht, Utrecht, CX, The Netherlands.
²⁸ Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal.
²⁹ Biomedical Sciences Institute (ICBAS), Porto University, Porto 4200-072, Portugal.
³⁰ South East Thames Genetics Service, Guy's Hospital, London SE1 9RT, UK.
³¹ Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne 50937, Germany.
³² McGill Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada.
³³ Duncan Guthrie Institute of Medical Genetics, Yorkhill NHS Trust, Glasgow G38SJ, UK.
³⁴ The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
³⁵ Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, HX 6229, The Netherlands.
³⁶ Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
³⁷ Churchill Hospital, Headington, Oxford OX3 7LE, UK.
³⁸ St George's Hospital, Tooting, London SW17 0QT, UK.
³⁹ Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle NE1 3BZ, UK.
⁴⁰ Parkville Familial Cancer Centre, The Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia.
⁴¹ Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3050, Australia.
⁴² Department of Medicine, The University of Melbourne, Parkville, VIC 3050, Australia.
⁴³ Karolinska University Hospital and Karolinska Institutet, Solna 171 77, Sweden.
⁴⁴ Familial Cancer Centre, Monash Health, Clayton, VIC 3168, Australia.
⁴⁵ VU University Medical Center, Amsterdam 1081 HV, The Netherlands.
⁴⁶ Familial Cancer Service, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
⁴⁷ Centre for Cancer Research, The Westmead Institute for Medical Research, Westmead, Sydney, NSW 2155, Australia.
⁴⁸ Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
⁴⁹ Genetic Health Queensland, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia.
⁵⁰ The Genetic Institute, Kaplan Medical Center, Rehovot 76100, Israel.
⁵¹ Genetic Services of WA, King Edward Memorial Hospital, Subiaco, WA 6008, Australia.
⁵² School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia.
⁵³ Hunter Family Cancer Service, Waratah, NSW 2298, Australia.
⁵⁴ University of New South Wales, St Vincent's Clinical School, NSW 2052, Australia.
⁵⁵ The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW 2010, Australia.
⁵⁶ NE Thames Regional Genetics Service, Great Ormond St Hospital & UCL Institute of Women's Health, London WC1N 3JH, UK.
⁵⁷ Institute of Oncology, Ljubljana 1000, Slovenia.
⁵⁸ Hospital de Sant Pau, Barcelona 08041, Spain.
⁵⁹ Peninsular Genetics, Derriford Hospital, Plymouth PL6 8DH, UK.
⁶⁰ Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK.
⁶¹ High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona 08035, Spain.
⁶² North West Thames Regional Genetics Service, London North West Healthcare NHS Trust, London HA1 3UJ, UK.
⁶³ St James' Hospital, Dublin 8, Ireland.
⁶⁴ Academic Medical Center, Amsterdam 1105 AZ, The Netherlands.
⁶⁵ St Michael's Hospital, Bristol BS2 8EG, UK.
⁶⁶ Landspitali-the National University Hospital of Iceland, Reykjavik 101, Iceland.
⁶⁷ University of Leicester, Leicester LE1 7RH, UK.
⁶⁸ University Hospitals Leicester, Leicester LE1 5WW, UK.
⁶⁹ Genetic Medicine, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.
⁷⁰ Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.
⁷¹ Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
⁷² Istituto Nazionale dei Tumori, Milano 20133, Italy.
⁷³ Cheshire and Mersey Clinical Genetics Service, Liverpool Women's Hospital, Liverpool L8 7SS, UK.
⁷⁴ Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
⁷⁵ Tata Memorial Centre, Mumbai, Maharashtra 400012, India.
⁷⁶ National Cancer Institute, Bratislava 83310, Slovak Republic.
⁷⁷ Cancer Research Initiatives Foundation, Subang Jaya Medical Centre, Subang Jaya, Selangor 47500, Darul Ehsan, Malaysia.
⁷⁸ The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
⁷⁹ Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01069, Germany.
⁸⁰ National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden 01307, Germany.
⁸¹ German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
⁸² Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid 28029, Spain.
⁸³ Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik 101, Iceland.
⁸⁴ Imperial College Healthcare NHS Trust, London, London W2 1NY, UK.
⁸⁵ HCA Healthcare Laboratories, London WC1E 6JA, UK.
⁸⁶ University Hospital, Umea 907 37, Sweden.
⁸⁷ Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 2JD, UK.
⁸⁸ University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK.
⁸⁹ CHS National Cancer Control Center, Carmel Medical Center, Haifa 3436212, Israel.
⁹⁰ Nottingham City Hospital, Nottingham NG5 1PB, UK.
⁹¹ Centre for Cancer Prevention, Queen Mary University of London, London EC1M 6BQ.
⁹² Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

PMID: 29301143
PMCID: PMC5785754
DOI: 10.1038/bjc.2017.429

Erratum in

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson … See abstract for full author list ➔ Mikropoulos C, et al. Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6. Br J Cancer. 2018. PMID: 29509747 Free PMC article.

Abstract

Background: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort.

Methods: PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of PSA or PSAV.

Results: 1634 participants had ⩾3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA >3.0 ng ml^-l, PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between BRCA status and last PSA before biopsy (P=0.031) and BRCA2 status and PSAV (P=0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers.

Conclusions: PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA value alone.

PubMed Disclaimer

Conflict of interest statement

Hans Lilja holds patents for free PSA, hK2, and intact PSA assays, and is named, along with Andrew J. Vickers, on a patent application for a statistical method to detect prostate cancer. The marker assay patents and the patent application for the statistical model has been licensed and commercialised as the 4Kscore by OPKO Diagnostics. Drs Vickers and Lilja receive royalties from sales of this test. Additionally, Dr Lilja owns stock and Dr Vickers owns stock options in OPKO. Professor Rosalind Eeles—Janssen: provided medical education support to GU ASCO Feb 2013. Succinct Communications: received an honorarium and expenses for attending and speaking at UK Cancer Convention Oct 2013. The authors have no other conflict of interest to declare.

Figures

**Figure 1**
**Consort diagram of study population.** The two bolded cohorts were included for in-depth analysis, as they had 3 or more PSA values available for analysis and underwent a prostate biopsy.

See this image and copyright information in PMC

References

1. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E IMPACT CollaboratorsMoss S, Eeles RA (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT Study. Eur Urol 66: 489–499. - PubMed
1. Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W (2005) Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64: 240–245. - PubMed
1. Bratt O, Loman N (2015) Clinical management of prostate cancer in men with BRCA mutations. Eur Urol 68: 194–195. - PubMed
1. Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316. - PubMed
1. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215–2220. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Affiliations

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous